An Efficient [2 + 2 + 1] Synthesis of 2,5-Disubstituted Oxazoles via Gold-Catalyzed Intermolecular Alkyne Oxidation
作者:Weimin He、Chaoqun Li、Liming Zhang
DOI:10.1021/ja2029188
日期:2011.6.8
reaction of gold carbene intermediates generated via gold-catalyzed alkyne oxidation has been realized using nitriles as both the reacting partner and the reaction solvent, offering a generally efficient synthesis of 2,5-disubstituted oxazoles with broad substrate scope. The overall reaction is a [2 + 2 + 1] annulation of a terminal alkyne, a nitrile, and an oxygen atom from an oxidant. The reaction conditions
A practicalone‐pot protocol for the synthesis of 2,5‐disubstitutedoxazoles from 1‐aryl‐2‐nitroethanones was reported. In the presence of iron/AcOH in acetonitrile, the reaction of 1‐aryl‐2‐nitroethanones with trimethyl orthoacetate or trimethyl orthobenzoate delivered the corresponding 2,5‐disubstitutedoxazoles in moderate to good yields.
[EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2014057435A1
公开(公告)日:2014-04-17
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
A Heterogeneous Gold(I)-Catalyzed [2 + 2 + 1] Annulation of Terminal Alkynes, Nitriles, and Oxygen Atoms Leading to 2,5-Disubstituted Oxazoles
作者:Weisen Yang、Rongli Zhang、Feiyan Yi、Mingzhong Cai
DOI:10.1021/acs.joc.7b00386
日期:2017.5.19
heterogeneous gold(I)-catalyzed [2 + 2 + 1] annulation of terminalalkynes, nitriles, and oxygen atoms has been achieved by using an MCM-41-immobilized phosphine–gold(I) complex as catalyst and 8-methylquinoline N-oxide as oxidant under mild conditions, yielding a variety of 2,5-disubstituted oxazoles in good to excellent yields with broad substrate scope. The new heterogeneous gold(I) catalyst can
OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
申请人:ACTELION PHARMACEUTICALS LTD
公开号:US20150252032A1
公开(公告)日:2015-09-10
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I)
wherein R, and the rings A
1
A
2
and A
3
are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.